Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal | Pharmasources.com
We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal

CPhI.CNMay 06, 2020

Tag: COVID-19 , neutralizing antibodies , Junshi Biosciences , SARS-CoV-2 , Editor's Picks

PharmaSources Customer Service